Interlaboratory validation of apixaban levels in ex vivo patient samples using a chromogenic anti-factor Xa assay

Int J Lab Hematol. 2020 Feb;42(1):e23-e26. doi: 10.1111/ijlh.13081. Epub 2019 Jul 9.

Authors

Jasmine Singh¹, Doen Ming Ong¹, Victoria Ling¹, Ming Sheng Lim², Erica Malan², Patricia Servadei³, Andrew Wallis¹, Giles Kelsey^{1

3}, Sanjeev Chunilal², Huyen Tran^{1

4}

Affiliations

¹ Laboratory Haematology, Alfred Hospital, Melbourne, Victoria, Australia.
² Monash Pathology, Monash Medical Centre, Clayton, Victoria, Australia.
³ Laboratory Haematology, Royal Melbourne Hospital, Parkville, Victoria, Australia.
⁴ Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia.

PMID: 31286666
DOI: 10.1111/ijlh.13081

No abstract available

Keywords: anticoagulants; apixaban; blood coagulation tests; clinical laboratory techniques; drug monitoring/methods.

Publication types

Letter

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Blood Coagulation Tests / standards
Chromogenic Compounds
Factor Xa Inhibitors / blood*
Factor Xa Inhibitors / standards
Female
Humans
Male
Middle Aged
Observer Variation
Pyrazoles / blood*
Pyrazoles / standards
Pyridones / blood*
Pyridones / standards
Reproducibility of Results

Substances

Chromogenic Compounds
Factor Xa Inhibitors
Pyrazoles
Pyridones
apixaban